BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 9166489)

  • 21. Taxol: initial Israeli experience with a novel anticancer agent.
    Sulkes A; Beller U; Peretz T; Shacter J; Hornreich G; McDaniel C; Winograd B
    Isr J Med Sci; 1994 Jan; 30(1):70-8. PubMed ID: 7908013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The taxanes: dosing and scheduling considerations.
    Rowinsky EK
    Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):7-19. PubMed ID: 9110338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Reduction of adverse reactions of anticancer agents with altered dose and schedule].
    Horikoshi N
    Nihon Rinsho; 2003 Jun; 61(6):1021-4. PubMed ID: 12806954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of phase II trials of Taxol (paclitaxel) in patients with advanced ovarian cancer.
    Einzig AI
    Ann Oncol; 1994; 5 Suppl 6():S29-32. PubMed ID: 7865430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.
    Synold TW; Doroshow JH
    J Infus Chemother; 1996; 6(2):69-73. PubMed ID: 8809652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
    Danesi R; Conte PF; Del Tacca M
    Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short versus long duration infusions of paclitaxel for any adenocarcinoma.
    Williams C; Collingwood M; Simera I; Grafton C
    Cochrane Database Syst Rev; 2003; (1):CD003911. PubMed ID: 12535492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infusional therapy with alkylating agents.
    Jones RB
    J Infus Chemother; 1996; 6(2):74-81. PubMed ID: 8809653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel.
    Cormio G; Di Vagno G; Melilli GA; Cazzolla A; Di Gesù G; Carriero C; Cramarossa D; Loverro G; Selvaggi L
    J Chemother; 1999 Oct; 11(5):407-9. PubMed ID: 10632389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylaxis for paclitaxel hypersensitivity reactions.
    Kintzel PE
    Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A preliminary risk-benefit assessment of paclitaxel.
    Bitton RJ; Figg WD; Reed E
    Drug Saf; 1995 Mar; 12(3):196-208. PubMed ID: 7619331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Theoretical and practical aspects of paclitaxel scheduling.
    Gianni L
    Ann Oncol; 1995 Nov; 6(9):861-3. PubMed ID: 8624286
    [No Abstract]   [Full Text] [Related]  

  • 33. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
    Hainsworth JD; Raefsky EL; Greco FA
    Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-agent paclitaxel for the treatment of breast cancer: an overview.
    Hortobagyi GN; Holmes FA
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):4-9. PubMed ID: 8629036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-72-S19-76. PubMed ID: 9427271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-hour paclitaxel infusions: review of safety and efficacy.
    Greco FA; Thomas M; Hainsworth JD
    Cancer J Sci Am; 1999; 5(3):179-91. PubMed ID: 10367176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel dose intensity.
    Reed E; Bitton R; Sarosy G; Kohn E
    J Infus Chemother; 1996; 6(2):59-63. PubMed ID: 8809650
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.